Category - Developments

Developments

Hepion Pharmaceuticals to present clinical data at NASH-TAG conference

Dr. Todd Hobbs, CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), will present data from the company’s Phase 2 AMBITION study with drug candidate, CRV431, at the NASH-TAG 2022 conference at Park City, Utah on Jan. 8...

January 5, 2022

Developments

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

In a letter to shareholders, chairman and CEO, Jim Joyce of Sigyn Therapeutics (OTC:SIGY), said that in the face of a pandemic that paused and shuttered numerous clinical research programs, “we translated our vision for...

January 4, 2022

Developments

PharmaJet partner Zydus Cadila in COVID-19 vaccine expansion with Korean firm

Needle-free injection company PharmaJet’s partner, Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine, ZyCoV-D, in Korea. The plan is to manufacture more than 80...

January 4, 2022

Developments

FSD Pharma in share repurchase program

The board of FSD Pharma (NASDAQ, CSE:HUGE; FRA: 0K9A) authorized the company to repurchase up to 2,000,000 of its subordinate Class B voting shares, or about 5% of its subordinate voting shares outstanding, from time to...

December 30, 2021

Developments

Altamira updates Bentrio EU roll-out, 510(k), new Asian distribution, COVID-19, allergy testing

Altamira Therapeutics (NASDAQ:CYTO) issued a business update on Bentrio, its nasal spray for protection against airborne viruses and allergens. The company has set up contracts with wholesalers in its lead market of...

December 30, 2021

Developments

Titan Pharmaceuticals to explore strategic alternatives

Titan Pharmaceuticals (NASDAQ:TTNP) engaged Maxim Group as its exclusive financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be...

December 21, 2021

Developments

FDA clears Hepion IND for CRV431 in treatment of liver cancer

The FDA accepted Hepion Pharmaceuticals’ (NASDAQ:HEPA) IND application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (HCC). Liver cancer is the sixth most...

December 21, 2021

Developments

Altamira randomizes first patients in Bentrio trial in house dust mite allergy

Altamira Therapeutics (NASDAQ:CYTO) randomized the first group of patients in a clinical trial with Bentrio (AM-301) in house dust mite allergic rhinitis. Bentrio, a drug-free nasal spray intended for personal...

December 16, 2021

Developments

Cidara, Mundipharma post positive Phase 3 results for rezafungin in candidemia, invasive candidiasis

Cidara Therapeutics (NASDAQ:CDTX) and Mundipharma reported positive topline data from the ReSTORE Phase 3 clinical trial, evaluating the efficacy and safety of its once-weekly antifungal...

December 15, 2021

Developments

Precigen reports positive interim Phase 1 data in r/r AML

Precigen (NASDAQ:PGEN) presented positive interim data at the ASH annual meeting from an ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T in patients with relapsed or refractory (r/r) acute myeloid leukemia...

December 14, 2021

Category - Developments

Hepion Pharmaceuticals to present clinical data at NASH-TAG conference

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

PharmaJet partner Zydus Cadila in COVID-19 vaccine expansion with Korean firm

FSD Pharma in share repurchase program

Altamira updates Bentrio EU roll-out, 510(k), new Asian distribution, COVID-19, allergy testing

Titan Pharmaceuticals to explore strategic alternatives

FDA clears Hepion IND for CRV431 in treatment of liver cancer

Altamira randomizes first patients in Bentrio trial in house dust mite allergy

Cidara, Mundipharma post positive Phase 3 results for rezafungin in candidemia, invasive candidiasis

Precigen reports positive interim Phase 1 data in r/r AML

General

More

Sign up for the BioTuesdays weekly newsletter